Drew Moghanaki: The phase III KEYNOTE-867 study results at ESMO 2024
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, shares on X:
“The phase III KEYNOTE-867 study results will be presented this week at ESMO24. The difference in G3 toxicity rates is impressive: only 3.7% with lung SBRT compared to 20% when adding Pembro. Also, G3 pneumonitis was 0% with lung SBRT alone.”
Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
Further Reading:
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023